See more : Hafnia Limited (HFIAF) Income Statement Analysis – Financial Results
Complete financial analysis of Cadrenal Therapeutics, Inc. Common Stock (CVKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cadrenal Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Coya Therapeutics, Inc. (COYA) Income Statement Analysis – Financial Results
- Forza Innovations Inc. (FORZ) Income Statement Analysis – Financial Results
- Vallourec S.A. (VLOWY) Income Statement Analysis – Financial Results
- Freshlocal Solutions Inc. (FLOCF) Income Statement Analysis – Financial Results
- Rizhao Port Jurong Co., Ltd. (6117.HK) Income Statement Analysis – Financial Results
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.98K | 1.27K |
| Gross Profit | -1.98K | -1.27K |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 4.08M | 392.86K |
| General & Administrative | 3.55M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 3.55M | 2.31M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 7.63M | 2.70M |
| Cost & Expenses | 7.63M | 2.70M |
| Interest Income | 249.09K | 0.00 |
| Interest Expense | 17.10K | 107.11K |
| Depreciation & Amortization | 1.98K | 1.27K |
| EBITDA | -8.34M | -6.61M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -7.63M | -2.70M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -724.24K | -4.01M |
| Income Before Tax | -8.36M | -6.71M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 |
| Net Income | -8.36M | -6.71M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -9.63 | -8.66 |
| EPS Diluted | -9.63 | -8.66 |
| Weighted Avg Shares Out | 868.18K | 775.64K |
| Weighted Avg Shares Out (Dil) | 868.18K | 775.64K |
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
PONTE VEDRA, Fla. , Feb. 26, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
PONTE VEDRA, Fla. , Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole...
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
PONTE VEDRA, Fla. , Jan. 31, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, cited today a recent peer-reviewed article in...
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
PONTE VEDRA, Fla. , Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
PONTE VEDRA, Fla. , Jan. 4, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
PONTE VEDRA, Fla., Dec. 19, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients...
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
PONTE VEDRA, Fla. , Dec. 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths (due to blood clots...
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
PONTE VEDRA, Fla. , Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
PONTE VEDRA, Fla. , Nov. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and...
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
PONTE VEDRA, Fla. , Oct. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Source: https://incomestatements.info
Category: Stock Reports